Personalised medicine

Personalised medicine is a high-value field, expected to expand significantly over the coming years. Strong IP strategy is key to successfully protecting emerging innovations that hold the potential to transform lives.  

The number of drug approvals in precision medicine is growing rapidly, yet this progress comes with significant legal and technical challenges. From navigating patent eligibility exclusions, to dealing with issues of ownership of data or divided infringement, while ensuring protection covers the constant evolution of assay platforms, good guidance is vital to success. 

Working with leading universities, research charities and pioneering SMEs, HGF’s large personalised medicine team delivers patent drafting and prosecution, due diligence and freedom to operate programmes, along with management of transactional and contentious matters in this revolutionary field.  

Our attorneys have a deep understanding of the challenges in this area.  With extensive in-house experience, we are able to tap into genuine insights to lead our clients’ IP strategies and advise across multiple jurisdictions. HGF’s perspective as European attorneys can help to identify global opportunities for clients from across the globe.

Latest updates

The draft of The Genetic Technology (Precision Breeding) Regulations 2025 reveals practical details on how to obtain a Precision Bred Organism status

In a recent blog post we discussed the Precision Breeding Regulatory Framework developed by the Food Standards Agency (FSA). Further details on the application process for Precision Bred Organism confirmation …

Read article

Regulation of NGT plants in Europe- Polish Presidency proposes an alternative solution to the Patent ban

In the latest development on the new proposed legislation for the regulation of NGT (gene-edited) plants in the EU, the Polish Presidency have proposed an amendment which removes the proposed …

Read article

Can the Chancellor’s so-called “Europe’s Silicon Valley” really replicate the innovative activity of its namesake?

The Chancellor of the UK, Rachel Reeves, recently unveiled plans to deliver an Oxford-Cambridge growth corridor that promises to boost the UK economy by up to £78 billion by 2035.  …

Read article

UPC on Doctrine of Equivalents

Plant-e Knowledge BV & anor v Arkyne Technologies SL UPC_CFI_239/2023 (Brinkman, Granata, Walker & Koke) – 22 November 2024 The Hague Local Division has handed down the first substantive UPC …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

Update on the Precision Breeding Act 2023: details emerge of the new simplified regulatory pathway for gene edited plant and animal derived food and feed products

The Genetic Technology (Precision Breeding) Act 2023 could come into force as early as spring 2025. It empowers the Food Standards Agency (FSA) to create a new simplified regulatory pathway …

Read article

Agritech Thymes: Arusha Protocol Enters into Force

Since being introduced in July 2015, the Arusha protocol for the protection of novel plant varieties in Africa has finally entered into force on the 24th of November 2024, after …

Read article

Agritech Thymes: The EPO Looks at the Morality and Patentability of Therapeutics Derived from Traditional Knowledge

This case (T2510/181) heard before the Technical Boards of Appeal at the EPO in May 2024 relates to the morality and novelty of substances of a natural origin. The invention …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our personalised medicine specialists.